Evaxion Biotech announced new data demonstrating its AI-Immunology platform's ability to identify endogenous retrovirus-derived antigens for potential glioblastoma cancer vaccines, to be presented at the AACR Annual Meeting on April 22, 2026.
Key takeaways
New data confirms AI-Immunology platform scalability for designing vaccines targeting glioblastoma, a deadly brain cancer with limited treatment options.
Collaboration with Duke University School of Medicine identified ERV-derived antigens and neoantigens in tumor samples from multiple glioblastoma patients.
ERV-derived antigens provide a novel target source potentially overcoming limitations of low mutational burden in glioblastoma tumors.
Findings will be presented at the AACR Annual Meeting in San Diego on April 22, 2026 (Poster #6975).